Osimertinib Active Not Recruiting Phase 1 / 2 Trials for EGFR Gene Mutations / Lung Cancer Non-Small Cell Cancer (NSCLC) Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment1 / 2
clinicaltrials.gov IdentifierTitleDrugs
NCT02789345A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer
NCT02908750Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC
NCT02197234Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC